A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ
Menée sur 327 patientes atteintes d'un carcinome canalaire in situ du sein et traitées par exérèse chirurgicale non combinée à une radiothérapie, cette étude évalue l'association entre le score DCIS, basé sur l'expression de plusieurs gènes associés à des cancers, et le risque de récidive locale
The incidence of ductal carcinoma in situ (DCIS) has seen a dramatic rise in the United States, particularly over the last three decades. Since the use of screening mammography in the 1980s and with improved technology, DCIS now accounts for 14% to 30% of all diagnosed breast cancers (1,2).
An ipsilateral breast event (IBE) remains the most common first failure event in DCIS management. Mastectomy was once the standard treatment for DCIS, with recurrence rates as low as 1.4% (3,4). Breast-conserving surgery (BCS) has now gained widespread acceptance as an alternative approach, based on the results of four randomized clinical studies led by the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-17 trial (5–8)...
Journal of the National Cancer Institute , éditorial en libre accès, 2013